{"id": "article-24243_0", "title": "Li-Fraumeni Syndrome -- Continuing Education Activity", "content": "Li Fraumeni syndrome, also known as sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, is a rare inherited autosomal dominant disorder associated with abnormalities in TP53, a tumor suppressor protein gene. This activity illustrates the evaluation and management of Li Fraumeni syndrome and reviews the role of the interprofessional team in improving care for patients with this condition.", "contents": "Li-Fraumeni Syndrome -- Continuing Education Activity. Li Fraumeni syndrome, also known as sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome, is a rare inherited autosomal dominant disorder associated with abnormalities in TP53, a tumor suppressor protein gene. This activity illustrates the evaluation and management of Li Fraumeni syndrome and reviews the role of the interprofessional team in improving care for patients with this condition."}
{"id": "article-24243_1", "title": "Li-Fraumeni Syndrome -- Continuing Education Activity", "content": "Objectives: Describe the role of TP53 in the etiology of Li Fraumeni syndrome. Explain the pathophysiology of Li Fraumeni syndrome. Summarize the Chompret criteria in the evaluation of Li Fraumeni syndrome. Review the importance of improving care coordination among the interprofessional team members to provide genetic counseling, medical care, and support services for patients affected by Li Fraumeni syndrome. Access free multiple choice questions on this topic.", "contents": "Li-Fraumeni Syndrome -- Continuing Education Activity. Objectives: Describe the role of TP53 in the etiology of Li Fraumeni syndrome. Explain the pathophysiology of Li Fraumeni syndrome. Summarize the Chompret criteria in the evaluation of Li Fraumeni syndrome. Review the importance of improving care coordination among the interprofessional team members to provide genetic counseling, medical care, and support services for patients affected by Li Fraumeni syndrome. Access free multiple choice questions on this topic."}
{"id": "article-24243_2", "title": "Li-Fraumeni Syndrome -- Introduction", "content": "In 1969, a remarkable cancer predisposition syndrome was reported by Li and Fraumeni. [1] Li-Fraumeni syndrome (LFS) is an inherited autosomal dominant disorder that is usually associated with abnormalities in the tumor suppressor protein P53 gene (TP53) located\u00a0on chromosome 17p13. [2] It is also known as the sarcoma, breast, leukemia, and adrenal gland (SBLA) cancer syndrome. LFS variants include LFS1, LFS2, LFSL. LFS1\u00a0is associated with mutations in TP53, a tumor suppressor gene. LFS2\u00a0is associated with mutations in CHEK2 (checkpoint kinase two), also a tumor suppressor gene. LFS-L are individuals that do not have detectable mutations in P53.", "contents": "Li-Fraumeni Syndrome -- Introduction. In 1969, a remarkable cancer predisposition syndrome was reported by Li and Fraumeni. [1] Li-Fraumeni syndrome (LFS) is an inherited autosomal dominant disorder that is usually associated with abnormalities in the tumor suppressor protein P53 gene (TP53) located\u00a0on chromosome 17p13. [2] It is also known as the sarcoma, breast, leukemia, and adrenal gland (SBLA) cancer syndrome. LFS variants include LFS1, LFS2, LFSL. LFS1\u00a0is associated with mutations in TP53, a tumor suppressor gene. LFS2\u00a0is associated with mutations in CHEK2 (checkpoint kinase two), also a tumor suppressor gene. LFS-L are individuals that do not have detectable mutations in P53."}
{"id": "article-24243_3", "title": "Li-Fraumeni Syndrome -- Etiology", "content": "There are three genes identified with Li-Fraumeni syndrome (LFS) Tp53 17p13, 1q23, and checkpoint kinase two genes CHEK2 locus at 22q12.1. [2] In these three genes, TP53 mutations are most common. P53 has many mechanisms of anticancer function; it plays a role in apoptosis, maintaining genomic stability, and inhibits angiogenesis. When DNA has sustained damage, it plays a role in the activation of DNA repair proteins. It can stop cell growth at the G1/S regulation point, which gives time for DNA repair proteins to fix the damage. If the damage is irreversible, it can trigger apoptosis. Checkpoint kinase 2 (Chek2) regulates the activities of P53. [3] [4]", "contents": "Li-Fraumeni Syndrome -- Etiology. There are three genes identified with Li-Fraumeni syndrome (LFS) Tp53 17p13, 1q23, and checkpoint kinase two genes CHEK2 locus at 22q12.1. [2] In these three genes, TP53 mutations are most common. P53 has many mechanisms of anticancer function; it plays a role in apoptosis, maintaining genomic stability, and inhibits angiogenesis. When DNA has sustained damage, it plays a role in the activation of DNA repair proteins. It can stop cell growth at the G1/S regulation point, which gives time for DNA repair proteins to fix the damage. If the damage is irreversible, it can trigger apoptosis. Checkpoint kinase 2 (Chek2) regulates the activities of P53. [3] [4]"}
{"id": "article-24243_4", "title": "Li-Fraumeni Syndrome -- Etiology", "content": "In TP53 mutations, one mutant allele\u00a0is\u00a0generally\u00a0inherited by individuals with Li-Fraumeni syndrome; the other allele\u00a0is\u00a0deleted or somatically mutated, which leads\u00a0to\u00a0loss of\u00a0functional\u00a0P53\u00a0protein.\u00a0Missense mutations are the most common to occur, usually in exons 5 to 8 which is the DNA binding region of the gene. When mutation testing is done targeting exons 5-8 (these are the usual targets for testing), nearly 70% of Li\u2013Fraumeni families meeting the required diagnostic criteria harbor P53 mutations. Partial loss of alleles presents with less family history, decreased numbers of tumors, and late disease onset. [5]", "contents": "Li-Fraumeni Syndrome -- Etiology. In TP53 mutations, one mutant allele\u00a0is\u00a0generally\u00a0inherited by individuals with Li-Fraumeni syndrome; the other allele\u00a0is\u00a0deleted or somatically mutated, which leads\u00a0to\u00a0loss of\u00a0functional\u00a0P53\u00a0protein.\u00a0Missense mutations are the most common to occur, usually in exons 5 to 8 which is the DNA binding region of the gene. When mutation testing is done targeting exons 5-8 (these are the usual targets for testing), nearly 70% of Li\u2013Fraumeni families meeting the required diagnostic criteria harbor P53 mutations. Partial loss of alleles presents with less family history, decreased numbers of tumors, and late disease onset. [5]"}
{"id": "article-24243_5", "title": "Li-Fraumeni Syndrome -- Etiology", "content": "Not all individuals with Li-Fraumeni syndrome have TP53 mutations. It also can\u00a0be due to an alteration in gene promoter which causes defective protein expression. It\u00a0may also be due\u00a0to new\u00a0mutations that have not been described.", "contents": "Li-Fraumeni Syndrome -- Etiology. Not all individuals with Li-Fraumeni syndrome have TP53 mutations. It also can\u00a0be due to an alteration in gene promoter which causes defective protein expression. It\u00a0may also be due\u00a0to new\u00a0mutations that have not been described."}
{"id": "article-24243_6", "title": "Li-Fraumeni Syndrome -- Epidemiology", "content": "Li-Fraumeni (LFS) is a rare syndrome, as over 500 families with LFS\u00a0have been reported in the literature. There are likely over 1,000 multigenerational families worldwide with LFS. Children with a diagnosis of adrenocortical carcinoma have the highest occurrence of P53 mutations. The syndrome is also\u00a0associated\u00a0with childhood brain tumors, osteosarcomas, and rhabdomyosarcomas. Patients with multiple primary tumors have a high incidence of P53 mutations. [6] [7]", "contents": "Li-Fraumeni Syndrome -- Epidemiology. Li-Fraumeni (LFS) is a rare syndrome, as over 500 families with LFS\u00a0have been reported in the literature. There are likely over 1,000 multigenerational families worldwide with LFS. Children with a diagnosis of adrenocortical carcinoma have the highest occurrence of P53 mutations. The syndrome is also\u00a0associated\u00a0with childhood brain tumors, osteosarcomas, and rhabdomyosarcomas. Patients with multiple primary tumors have a high incidence of P53 mutations. [6] [7]"}
{"id": "article-24243_7", "title": "Li-Fraumeni Syndrome -- Epidemiology", "content": "Mutations in the core binding protein of TP53 have an increased risk of cancer. TP53 mutations have a high penetrance. The lifetime risk for women is 90 percent by age 60 years while in men the estimated lifetime risk is about 73 percent. [8] While most hereditary family cancer syndromes involve specific tumor types, members of LFS are at risk for a wide range of malignancies, with particular\u00a0occurrences of breast cancer, bone sarcomas, and soft tissue sarcomas. Several other cancers have been reported but at a lower incidence in Li-Fraumeni syndrome. [9]", "contents": "Li-Fraumeni Syndrome -- Epidemiology. Mutations in the core binding protein of TP53 have an increased risk of cancer. TP53 mutations have a high penetrance. The lifetime risk for women is 90 percent by age 60 years while in men the estimated lifetime risk is about 73 percent. [8] While most hereditary family cancer syndromes involve specific tumor types, members of LFS are at risk for a wide range of malignancies, with particular\u00a0occurrences of breast cancer, bone sarcomas, and soft tissue sarcomas. Several other cancers have been reported but at a lower incidence in Li-Fraumeni syndrome. [9]"}
{"id": "article-24243_8", "title": "Li-Fraumeni Syndrome -- Epidemiology", "content": "The risk of developing multiple primary cancers is high in members of families with Li-Fraumeni syndrome compared to the general population. This excess risk mainly involves cancers characteristic of LFS, this\u00a0risk\u00a0is further increased in survivors\u00a0of childhood cancers, and these patients require close monitoring for early cancer signs. [10]", "contents": "Li-Fraumeni Syndrome -- Epidemiology. The risk of developing multiple primary cancers is high in members of families with Li-Fraumeni syndrome compared to the general population. This excess risk mainly involves cancers characteristic of LFS, this\u00a0risk\u00a0is further increased in survivors\u00a0of childhood cancers, and these patients require close monitoring for early cancer signs. [10]"}
{"id": "article-24243_9", "title": "Li-Fraumeni Syndrome -- Epidemiology", "content": "Patients with\u00a0LFS\u00a0are\u00a0successfully treated during the initial cancer occurrence. However, radiation therapy should be avoided, when possible, due to several case reports and preclinical evidence showing an increased risk of radiation-induced cancers in these patients. [11] Li-Fraumeni patients are at a high risk of developing a second primary malignancy. [12]", "contents": "Li-Fraumeni Syndrome -- Epidemiology. Patients with\u00a0LFS\u00a0are\u00a0successfully treated during the initial cancer occurrence. However, radiation therapy should be avoided, when possible, due to several case reports and preclinical evidence showing an increased risk of radiation-induced cancers in these patients. [11] Li-Fraumeni patients are at a high risk of developing a second primary malignancy. [12]"}
{"id": "article-24243_10", "title": "Li-Fraumeni Syndrome -- Pathophysiology", "content": "Li-Fraumeni syndrome (LFS) occurs due to germ-line mutations in TP53. TP53 is a tumor suppressor gene, which\u00a0is located on band 17p13.1, which codes for a 53-kD nuclear protein transcription factor that has important regulatory control over cell proliferation and homeostasis, specifically apoptosis, DNA repair, and cell cycle. Mutations can arise in one of the parent's germ cells, de novo during embryogenesis, or can be inherited. Changes in P53 function results from either increased or aberrant protein function or loss of function of wild-type P53. Most\u00a0Li-Fraumeni syndrome TP53 mutations occur as missense point mutations in a hot-spot region of exons 5-8. [13] This\u00a0is the gene portion that codes for the core DNA-binding domain of the protein. This kind of mutation leads to stable but inactive protein, which accumulates in the nucleus of tumor cells. Any mutation like frameshift, nonsense and splice-site can also be present but do not lead to the accumulation of p53 protein.", "contents": "Li-Fraumeni Syndrome -- Pathophysiology. Li-Fraumeni syndrome (LFS) occurs due to germ-line mutations in TP53. TP53 is a tumor suppressor gene, which\u00a0is located on band 17p13.1, which codes for a 53-kD nuclear protein transcription factor that has important regulatory control over cell proliferation and homeostasis, specifically apoptosis, DNA repair, and cell cycle. Mutations can arise in one of the parent's germ cells, de novo during embryogenesis, or can be inherited. Changes in P53 function results from either increased or aberrant protein function or loss of function of wild-type P53. Most\u00a0Li-Fraumeni syndrome TP53 mutations occur as missense point mutations in a hot-spot region of exons 5-8. [13] This\u00a0is the gene portion that codes for the core DNA-binding domain of the protein. This kind of mutation leads to stable but inactive protein, which accumulates in the nucleus of tumor cells. Any mutation like frameshift, nonsense and splice-site can also be present but do not lead to the accumulation of p53 protein."}
{"id": "article-24243_11", "title": "Li-Fraumeni Syndrome -- Pathophysiology", "content": "The cell loses protection against genetic alterations when P53 mutations occur. Ubiquitin ligase HDM2 and P53 interact with E3 and E4 proteins, which induce polyubiquitination and degradation of P53,\u00a0which prevents apoptosis. [14] [15] They are also associated with the overexpression of UBE4B and with the amplification of these genes in brain tumors. The absence of P53 mutations in some families indicates that P53 protein may undergo posttranslational modifications, or other genes may\u00a0be involved. Genetic copy number variation, used as an indicator of genetic instability, are higher in patients with germline TP53 mutations than in healthy individuals.", "contents": "Li-Fraumeni Syndrome -- Pathophysiology. The cell loses protection against genetic alterations when P53 mutations occur. Ubiquitin ligase HDM2 and P53 interact with E3 and E4 proteins, which induce polyubiquitination and degradation of P53,\u00a0which prevents apoptosis. [14] [15] They are also associated with the overexpression of UBE4B and with the amplification of these genes in brain tumors. The absence of P53 mutations in some families indicates that P53 protein may undergo posttranslational modifications, or other genes may\u00a0be involved. Genetic copy number variation, used as an indicator of genetic instability, are higher in patients with germline TP53 mutations than in healthy individuals."}
{"id": "article-24243_12", "title": "Li-Fraumeni Syndrome -- Pathophysiology -- Mutations Associated with Younger Age of Onset in Li-Fraumeni Syndrome", "content": "Short telomeres Genetic modifiers, including the MDM2-SNP309 polymorphism, and genetic anticipation P53-related cancers, usually breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands), and other cancers [16] [17] [18]", "contents": "Li-Fraumeni Syndrome -- Pathophysiology -- Mutations Associated with Younger Age of Onset in Li-Fraumeni Syndrome. Short telomeres Genetic modifiers, including the MDM2-SNP309 polymorphism, and genetic anticipation P53-related cancers, usually breast cancer, soft tissue sarcoma, osteosarcoma (bone cancer), leukemia, brain tumors, adrenocortical carcinoma (cancer of the adrenal glands), and other cancers [16] [17] [18]"}
{"id": "article-24243_13", "title": "Li-Fraumeni Syndrome -- History and Physical", "content": "The family history of cancer, young age at initial diagnosis, and multiple malignancies suggest cancer syndromes that are hereditary. Patients should be informed adequately about all the signs and symptoms of cancer. They must be counseled to consult whenever they have any unusual signs or symptoms related to cancer. A complete family history of multiple generations is very important\u00a0due to a significant increase in cancer risk within families. [19] The history should include screening for multiple tumor types especially sarcomas, breast, leukemia, and adrenocortical tumors. [20] Sometimes risk becomes evident only after several years, so it is very important to update the family history regularly.\u00a0Obtaining a thorough family history can be difficult, but it is an important part of evaluating every child diagnosed with an early malignancy. History should emphasize all cancers in the Li-Fraumeni syndrome spectrum. [21]", "contents": "Li-Fraumeni Syndrome -- History and Physical. The family history of cancer, young age at initial diagnosis, and multiple malignancies suggest cancer syndromes that are hereditary. Patients should be informed adequately about all the signs and symptoms of cancer. They must be counseled to consult whenever they have any unusual signs or symptoms related to cancer. A complete family history of multiple generations is very important\u00a0due to a significant increase in cancer risk within families. [19] The history should include screening for multiple tumor types especially sarcomas, breast, leukemia, and adrenocortical tumors. [20] Sometimes risk becomes evident only after several years, so it is very important to update the family history regularly.\u00a0Obtaining a thorough family history can be difficult, but it is an important part of evaluating every child diagnosed with an early malignancy. History should emphasize all cancers in the Li-Fraumeni syndrome spectrum. [21]"}
{"id": "article-24243_14", "title": "Li-Fraumeni Syndrome -- History and Physical", "content": "No specific physical findings\u00a0are seen in individuals affected by Li-Fraumeni syndrome that differ from the findings related to specific cancers.\u00a0Physical findings to watch for in specific cancers include: Neurologic features\u00a0like seizures, vomiting, headaches, and gait changes related to brain cancers A breast lump in breast cancer Soft-tissue mass or a bone-related mass in soft tissue sarcoma or bone sarcoma Pancytopenia, fatigue, fever, weight loss, loss of appetite, swollen lymph nodes, bleeding gums, and infections in acute leukemia Virilization including prepubertal genital hair, increased penile size, clitoromegaly, deep voice associated with an abdominal mass in adrenal cortical carcinoma [19] [22] An annual\u00a0physical examination should be performed, including breast, skin, and neurological assessments.", "contents": "Li-Fraumeni Syndrome -- History and Physical. No specific physical findings\u00a0are seen in individuals affected by Li-Fraumeni syndrome that differ from the findings related to specific cancers.\u00a0Physical findings to watch for in specific cancers include: Neurologic features\u00a0like seizures, vomiting, headaches, and gait changes related to brain cancers A breast lump in breast cancer Soft-tissue mass or a bone-related mass in soft tissue sarcoma or bone sarcoma Pancytopenia, fatigue, fever, weight loss, loss of appetite, swollen lymph nodes, bleeding gums, and infections in acute leukemia Virilization including prepubertal genital hair, increased penile size, clitoromegaly, deep voice associated with an abdominal mass in adrenal cortical carcinoma [19] [22] An annual\u00a0physical examination should be performed, including breast, skin, and neurological assessments."}
{"id": "article-24243_15", "title": "Li-Fraumeni Syndrome -- Evaluation", "content": "Initially, the diagnosis of Li-Fraumeni\u00a0was done using clinical criteria based on signs and symptoms the patient and family have. With advanced genetic testing, patients can now know if they carry a copy of the TP53 tumor mutation before showing any signs of LFS. Genetic testing for TP53 mutations is very important. It is important\u00a0to offer genetic counseling and testing to all relatives at risk of having a familial TP53 pathogenic variant. Genetic testing only detects approximately 70% to 75% of cases. Genetic counseling\u00a0must\u00a0be done to consider\u00a0genetic testing,\u00a0and if it concludes that a patient is carrying a copy of TP53 mutations,\u00a0the patient must\u00a0be counseled about surveillance and continuously\u00a0screened for LFS related types of cancer. [23] The decision to do genetic\u00a0counseling\u00a0and TP53 mutation testing\u00a0should be considered\u00a0for the following patients:", "contents": "Li-Fraumeni Syndrome -- Evaluation. Initially, the diagnosis of Li-Fraumeni\u00a0was done using clinical criteria based on signs and symptoms the patient and family have. With advanced genetic testing, patients can now know if they carry a copy of the TP53 tumor mutation before showing any signs of LFS. Genetic testing for TP53 mutations is very important. It is important\u00a0to offer genetic counseling and testing to all relatives at risk of having a familial TP53 pathogenic variant. Genetic testing only detects approximately 70% to 75% of cases. Genetic counseling\u00a0must\u00a0be done to consider\u00a0genetic testing,\u00a0and if it concludes that a patient is carrying a copy of TP53 mutations,\u00a0the patient must\u00a0be counseled about surveillance and continuously\u00a0screened for LFS related types of cancer. [23] The decision to do genetic\u00a0counseling\u00a0and TP53 mutation testing\u00a0should be considered\u00a0for the following patients:"}
{"id": "article-24243_16", "title": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria", "content": "Classic Li-Fraumeni syndrome - It is\u00a0diagnosed\u00a0when the person has all the following criteria: [24] A sarcoma diagnosed before age 45. A first-degree relative, parent, sibling, or child with any cancer before age 45. Any cancer before age 45 or a sarcoma at any age in first-degree or second-degree relative (grandparent, aunt/uncle, niece/nephew, or grandchild). Chompret Criteria [25]", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria. Classic Li-Fraumeni syndrome - It is\u00a0diagnosed\u00a0when the person has all the following criteria: [24] A sarcoma diagnosed before age 45. A first-degree relative, parent, sibling, or child with any cancer before age 45. Any cancer before age 45 or a sarcoma at any age in first-degree or second-degree relative (grandparent, aunt/uncle, niece/nephew, or grandchild). Chompret Criteria [25]"}
{"id": "article-24243_17", "title": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria", "content": "This includes brain tumor, adrenocortical cancer, breast cancer in the proband, and also has a lower age cutoff of <31 years. Consider a diagnosis of LFS for anyone with a personal and family history that meets one of the following three criteria. A tumor belonging to the LFS spectrum before the age of 46. This includes any of these diseases: premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, adrenal cortical tumor, brain tumor, leukemia, lung cancer. AND At least one first- or second-degree relative with an LFS tumor before age 56 years or multiple tumors, except for breast cancer if the proband has breast cancer. A person with multiple tumors, except\u00a0when two\u00a0belong to the LFS tumor spectrum with the first occurring before age 46. A person who is diagnosed with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history. Li-Fraumeni-like syndrome (LFL) is another term for families who do not meet the set classic criteria. LFL-1, Birch Definition [26]", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria. This includes brain tumor, adrenocortical cancer, breast cancer in the proband, and also has a lower age cutoff of <31 years. Consider a diagnosis of LFS for anyone with a personal and family history that meets one of the following three criteria. A tumor belonging to the LFS spectrum before the age of 46. This includes any of these diseases: premenopausal breast cancer, soft tissue sarcoma, osteosarcoma, adrenal cortical tumor, brain tumor, leukemia, lung cancer. AND At least one first- or second-degree relative with an LFS tumor before age 56 years or multiple tumors, except for breast cancer if the proband has breast cancer. A person with multiple tumors, except\u00a0when two\u00a0belong to the LFS tumor spectrum with the first occurring before age 46. A person who is diagnosed with adrenocortical carcinoma or choroid plexus tumor, irrespective of family history. Li-Fraumeni-like syndrome (LFL) is another term for families who do not meet the set classic criteria. LFL-1, Birch Definition [26]"}
{"id": "article-24243_18", "title": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria", "content": "A person diagnosed with any brain tumor,\u00a0adrenocortical tumor, sarcoma, breast cancer\u00a0before age 45 AND A typical LFS cancer in a first or second-degree relative\u00a0at any age. AND A first-degree or second-degree relative with any cancer before age 60. LFL-2, ELES Criteria [26] Two relatives (first-degree or second-degree) diagnosed with a typical LFS cancer at any age.", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria. A person diagnosed with any brain tumor,\u00a0adrenocortical tumor, sarcoma, breast cancer\u00a0before age 45 AND A typical LFS cancer in a first or second-degree relative\u00a0at any age. AND A first-degree or second-degree relative with any cancer before age 60. LFL-2, ELES Criteria [26] Two relatives (first-degree or second-degree) diagnosed with a typical LFS cancer at any age."}
{"id": "article-24243_19", "title": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria", "content": "Individuals who have either classical criteria for LFS or the Chompret criteria or who have other combinations of cancer and family history that put them at risk for LFS or LFL syndrome, but in whom there is no known mutation in the family. Negative test results do not rule out LFS and these patients should be managed as if they have LFS. Women with early-onset breast cancer (less than 31 years) and without a detectable breast cancer gene 1 (BRCA1) or 2 (BRCA2) mutation. It increases the index of suspicion for Li-Fraumeni syndrome if there is a family history of sarcoma, brain tumor, or adrenocortical carcinoma. A negative result in these individuals does not rule out LFS. [27] Patients with a family history of known TP53 mutation to test for the known mutation. A negative test in these individuals rules out LFS. Those who choose not to undergo testing should be managed as if they harbor the\u00a0TP53\u00a0mutation, at least until 50 years of age.", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria. Individuals who have either classical criteria for LFS or the Chompret criteria or who have other combinations of cancer and family history that put them at risk for LFS or LFL syndrome, but in whom there is no known mutation in the family. Negative test results do not rule out LFS and these patients should be managed as if they have LFS. Women with early-onset breast cancer (less than 31 years) and without a detectable breast cancer gene 1 (BRCA1) or 2 (BRCA2) mutation. It increases the index of suspicion for Li-Fraumeni syndrome if there is a family history of sarcoma, brain tumor, or adrenocortical carcinoma. A negative result in these individuals does not rule out LFS. [27] Patients with a family history of known TP53 mutation to test for the known mutation. A negative test in these individuals rules out LFS. Those who choose not to undergo testing should be managed as if they harbor the\u00a0TP53\u00a0mutation, at least until 50 years of age."}
{"id": "article-24243_20", "title": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria", "content": "Individuals with some cancers irrespective of age or family history should undergo genetic testing for TP53 deleterious gene mutations. These include a) adrenocortical carcinoma b) choroid plexus carcinoma at any age c) rhabdomyosarcoma before age three years d) osteosarcoma before age ten years e) childhood sarcoma (except Ewing sarcoma). [28] Consider prenatal testing for at-risk pregnancies in situations where a specific TP53 mutation has been identified.", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Diagnostic Criteria. Individuals with some cancers irrespective of age or family history should undergo genetic testing for TP53 deleterious gene mutations. These include a) adrenocortical carcinoma b) choroid plexus carcinoma at any age c) rhabdomyosarcoma before age three years d) osteosarcoma before age ten years e) childhood sarcoma (except Ewing sarcoma). [28] Consider prenatal testing for at-risk pregnancies in situations where a specific TP53 mutation has been identified."}
{"id": "article-24243_21", "title": "Li-Fraumeni Syndrome -- Evaluation -- Cancer Surveillance", "content": "Cancer surveillance\u00a0is required for individuals who\u00a0are at risk based on the history of LFS malignancy, the patient with known\u00a0TP53 tumor mutation, or those with increased risk in a family with LFS but without an identifiable mutation or who have not undergone mutation testing. [12] [29] [30]", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Cancer Surveillance. Cancer surveillance\u00a0is required for individuals who\u00a0are at risk based on the history of LFS malignancy, the patient with known\u00a0TP53 tumor mutation, or those with increased risk in a family with LFS but without an identifiable mutation or who have not undergone mutation testing. [12] [29] [30]"}
{"id": "article-24243_22", "title": "Li-Fraumeni Syndrome -- Evaluation -- Cancer Surveillance", "content": "Complete annual physical examination and medical evaluation for unexplained symptoms Whole-body magnetic resonance imaging (WBMRI) annually Abdominal and pelvic ultrasound (US) every 3 to 4 months in children and annually in the adult Biochemical markers for adrenocortical functions Blood tests every 4 months (complete blood count, lactate dehydrogenase, and erythrocyte sedimentation rate) Breast cancer monitoring - breast self-examination monthly, biannual clinical breast examination with a healthcare provider, and annual breast imaging beginning at age 20 to 25 years (preferably MRI breast due to radiation\u00a0exposure from mammography) Colonoscopy every 2 to 5 years, beginning at age 25 to 30 or 5 years before the earliest known colon cancer in the family Blood test for biochemical markers and brain MRI as per Toronto protocol", "contents": "Li-Fraumeni Syndrome -- Evaluation -- Cancer Surveillance. Complete annual physical examination and medical evaluation for unexplained symptoms Whole-body magnetic resonance imaging (WBMRI) annually Abdominal and pelvic ultrasound (US) every 3 to 4 months in children and annually in the adult Biochemical markers for adrenocortical functions Blood tests every 4 months (complete blood count, lactate dehydrogenase, and erythrocyte sedimentation rate) Breast cancer monitoring - breast self-examination monthly, biannual clinical breast examination with a healthcare provider, and annual breast imaging beginning at age 20 to 25 years (preferably MRI breast due to radiation\u00a0exposure from mammography) Colonoscopy every 2 to 5 years, beginning at age 25 to 30 or 5 years before the earliest known colon cancer in the family Blood test for biochemical markers and brain MRI as per Toronto protocol"}
{"id": "article-24243_23", "title": "Li-Fraumeni Syndrome -- Treatment / Management", "content": "There is currently\u00a0no procedure or treatment option to repair mutations in the P53 gene as P53 is not a drug target yet. In general, radiation therapy should be avoided in patients with Li-Fraumeni syndrome\u00a0as individuals are at high risk of radiation-induced secondary cancers. Similarly, exposure to computed tomography (CT) scans or X-rays should be avoided. [31] Li-Fraumeni syndrome is a\u00a0complex syndrome with many implications for individuals and their families, so it is suggested patients with\u00a0LFS\u00a0or suspected\u00a0LFS\u00a0consult with a physician or health care system that has experience\u00a0in treating patients with Li-Fraumeni syndrome and providing medical care, genetic counseling, and special support services. [19] [32]", "contents": "Li-Fraumeni Syndrome -- Treatment / Management. There is currently\u00a0no procedure or treatment option to repair mutations in the P53 gene as P53 is not a drug target yet. In general, radiation therapy should be avoided in patients with Li-Fraumeni syndrome\u00a0as individuals are at high risk of radiation-induced secondary cancers. Similarly, exposure to computed tomography (CT) scans or X-rays should be avoided. [31] Li-Fraumeni syndrome is a\u00a0complex syndrome with many implications for individuals and their families, so it is suggested patients with\u00a0LFS\u00a0or suspected\u00a0LFS\u00a0consult with a physician or health care system that has experience\u00a0in treating patients with Li-Fraumeni syndrome and providing medical care, genetic counseling, and special support services. [19] [32]"}
{"id": "article-24243_24", "title": "Li-Fraumeni Syndrome -- Treatment / Management", "content": "No evidence suggests that individuals with LFS diagnosed with cancers should be treated uniquely from other patients with the same cancer. However, in breast cancer, complete mastectomy rather than lumpectomy which is usually\u00a0followed by radiation therapy is generally preferred because of the risks of second breast cancers or radiation-induced neoplasms. [33] [34] Physicians should discuss the need for risk-reducing mastectomy; it must\u00a0be considered case-by-case, depending on the degree of\u00a0cancer risk and reconstructive options. Li-Fraumeni syndrome patients are prone to anxiety, depression, and clinically relevant distress. Psychological monitoring is\u00a0recommended and providing support is very important.", "contents": "Li-Fraumeni Syndrome -- Treatment / Management. No evidence suggests that individuals with LFS diagnosed with cancers should be treated uniquely from other patients with the same cancer. However, in breast cancer, complete mastectomy rather than lumpectomy which is usually\u00a0followed by radiation therapy is generally preferred because of the risks of second breast cancers or radiation-induced neoplasms. [33] [34] Physicians should discuss the need for risk-reducing mastectomy; it must\u00a0be considered case-by-case, depending on the degree of\u00a0cancer risk and reconstructive options. Li-Fraumeni syndrome patients are prone to anxiety, depression, and clinically relevant distress. Psychological monitoring is\u00a0recommended and providing support is very important."}
{"id": "article-24243_25", "title": "Li-Fraumeni Syndrome -- Differential Diagnosis", "content": "Hereditary breast and ovarian cancer syndrome (HBOC) Lynch syndrome Multiple endocrine neoplasia [35]", "contents": "Li-Fraumeni Syndrome -- Differential Diagnosis. Hereditary breast and ovarian cancer syndrome (HBOC) Lynch syndrome Multiple endocrine neoplasia [35]"}
{"id": "article-24243_26", "title": "Li-Fraumeni Syndrome -- Prognosis", "content": "There is no difference in the treatment of cancers in LFS and other cancers that occur sporadically. Advancement in the treatment of childhood cancers has increased the long-term survival for most children. Usual complications in survivors include second\u00a0primary malignancies, which mostly occur within 6 to 12 years after the first cancer. [36] [37]", "contents": "Li-Fraumeni Syndrome -- Prognosis. There is no difference in the treatment of cancers in LFS and other cancers that occur sporadically. Advancement in the treatment of childhood cancers has increased the long-term survival for most children. Usual complications in survivors include second\u00a0primary malignancies, which mostly occur within 6 to 12 years after the first cancer. [36] [37]"}
{"id": "article-24243_27", "title": "Li-Fraumeni Syndrome -- Prognosis", "content": "A second cancer may occur due to genetic predispositions such as constitutional\u00a0TP53\u00a0mutations. The risk for a second cancer increases with younger age at diagnosis of first cancer. Second cancer risk increases with radiation exposure,\u00a0so these individuals should avoid or minimize exposure to diagnostic and therapeutic radiation when possible. They have a predilection for developing subsequent primary tumors (especially sarcomas) in prior radiation fields. [7] [38] The cumulative probability of a person affected by LFS developing a second cancer is close to 60% at 30 years after developing the first cancer.", "contents": "Li-Fraumeni Syndrome -- Prognosis. A second cancer may occur due to genetic predispositions such as constitutional\u00a0TP53\u00a0mutations. The risk for a second cancer increases with younger age at diagnosis of first cancer. Second cancer risk increases with radiation exposure,\u00a0so these individuals should avoid or minimize exposure to diagnostic and therapeutic radiation when possible. They have a predilection for developing subsequent primary tumors (especially sarcomas) in prior radiation fields. [7] [38] The cumulative probability of a person affected by LFS developing a second cancer is close to 60% at 30 years after developing the first cancer."}
{"id": "article-24243_28", "title": "Li-Fraumeni Syndrome -- Complications", "content": "Individuals with Li-Fraumeni syndrome can become resistant to chemotherapy. The risk of other primary cancers is increased if a germline mutation has occurred. There is evidence that a\u00a0TP53\u00a0genetic mutation can cause a patient to have an increased sensitivity to ionizing radiation. Individuals with germline\u00a0TP53\u00a0mutations should avoid or minimize exposure to diagnostic and therapeutic radiation when possible. [39]", "contents": "Li-Fraumeni Syndrome -- Complications. Individuals with Li-Fraumeni syndrome can become resistant to chemotherapy. The risk of other primary cancers is increased if a germline mutation has occurred. There is evidence that a\u00a0TP53\u00a0genetic mutation can cause a patient to have an increased sensitivity to ionizing radiation. Individuals with germline\u00a0TP53\u00a0mutations should avoid or minimize exposure to diagnostic and therapeutic radiation when possible. [39]"}
{"id": "article-24243_29", "title": "Li-Fraumeni Syndrome -- Consultations", "content": "Referral to a genetic counselor is recommended to obtain a detailed family history, genetic counseling, discuss risks of cancer, and plan for cancer screening. [40] [41] [42]", "contents": "Li-Fraumeni Syndrome -- Consultations. Referral to a genetic counselor is recommended to obtain a detailed family history, genetic counseling, discuss risks of cancer, and plan for cancer screening. [40] [41] [42]"}
{"id": "article-24243_30", "title": "Li-Fraumeni Syndrome -- Deterrence and Patient Education", "content": "Parents and patients should be informed adequately about all the signs and symptoms of cancer. They must be counseled to\u00a0seek care whenever they have any unusual signs or symptoms that may be related to a cancer. Patients should\u00a0be trained\u00a0to perform a breast self-examination regularly every month, starting at age 18 years. Psychological monitoring is very important as these patients can develop anxiety or depression.", "contents": "Li-Fraumeni Syndrome -- Deterrence and Patient Education. Parents and patients should be informed adequately about all the signs and symptoms of cancer. They must be counseled to\u00a0seek care whenever they have any unusual signs or symptoms that may be related to a cancer. Patients should\u00a0be trained\u00a0to perform a breast self-examination regularly every month, starting at age 18 years. Psychological monitoring is very important as these patients can develop anxiety or depression."}
{"id": "article-24243_31", "title": "Li-Fraumeni Syndrome -- Enhancing Healthcare Team Outcomes", "content": "The management of patients with Li-Fraumeni syndrome is best accomplished with an interprofessional team approach involving a geneticist, internist, oncologist, psychiatrist,\u00a0and radiologist. Li-Fraumeni syndrome patients are prone to anxiety, depression, and clinically relevant distress. Psychological monitoring by an interprofessional\u00a0team of oncology specialty nurses and oncologists is important and providing support is very important for good outcomes. [Level 5]", "contents": "Li-Fraumeni Syndrome -- Enhancing Healthcare Team Outcomes. The management of patients with Li-Fraumeni syndrome is best accomplished with an interprofessional team approach involving a geneticist, internist, oncologist, psychiatrist,\u00a0and radiologist. Li-Fraumeni syndrome patients are prone to anxiety, depression, and clinically relevant distress. Psychological monitoring by an interprofessional\u00a0team of oncology specialty nurses and oncologists is important and providing support is very important for good outcomes. [Level 5]"}
{"id": "article-24243_32", "title": "Li-Fraumeni Syndrome -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Li-Fraumeni Syndrome -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}